Showing 7681-7690 of 8856 results for "".
- L'Oréal's SkinCeuticals Taps New GMhttps://practicaldermatology.com/news/loreals-skinceuticals-taps-new-gm/2460621/Stephanie Kramer is L'Oréal's SkinCeuticals new General Manager. Kramer was Global Senior Vice President of Marketing, Product Innovation and Retail at SkinCeuticals. Prior to joining SkinCeuticals in 2019, Kramer served as Vice President of Global Marketi
- Study: Iron Oxides Offer Protection Skin from Blue Lighthttps://practicaldermatology.com/news/study-iron-oxides-protection-skin-from-blue-light/2460616/Iron oxides provide enhanced protection against HEV or blue light, especially when combined with zinc oxide, according to results of a new study in The Journal of Cosmetic Dermatology. HEV
- Online Booking Functionality Comes to Demandforcehttps://practicaldermatology.com/news/online-booking-functionality-comes-to-demandforce/2460615/Demandforce has launched Demandforce Online Booking, a new functionality that makes it easier for clients of Demandforce business users to schedule appointments online while enabling businesses to manage their appointment sche
- Research Identifies Long-Term Benefits of Incorporating Ceramides into Baby Skincarehttps://practicaldermatology.com/news/research-identifies-long-term-benefits-of-incorporating-ceramides-into-baby-skincare/2460612/Using ceramide-infused products on baby skin may have long-term benefits lasting into adulthood, according to a newly published study in the Journal of Drugs in Dermatology. Beyond n
- Study: “Baby Botox” Boosts Skin Texture, Shrinks Poreshttps://practicaldermatology.com/news/study-baby-botox-boosts-skin-texture-shrinks-pores/2460603/Using many tiny doses of botulinum toxin injected in a grid pattern just under the surface of the facial skin may improve skin texture and roughness, according to a
- Tremfya Reduces Fatigue in PsAhttps://practicaldermatology.com/news/tremfya-reduces-fatigue-in-psa/2460602/The IL-23 blocker Tremfya (guselkumab) improves fatigue in adult patients with active psoriatic arthritis (PsA) and this response is maintained through 52 weeks of active treatment, according to data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2. Tremfya improved
- Cosentyx Shows Early Synovitis Reduction in PsAhttps://practicaldermatology.com/news/cosentyx-shows-early-synovitis-reduction-in-psa/2460600/Cosentyx (secukinumab) showed early reduction of synovitis in psoriatic arthritis (PsA), according to the Phase IIIb ULTIMATE trial which will be presented at the American College of Rheumatology (ACR) All-Virtual Annual Meeting. Specifically, a significant reduction of synovitis&n
- Cutera Gives Back: Company Donates Tattoo Removal Laser to Gang Rehabilitation and Re-entry Programhttps://practicaldermatology.com/news/cutera-gives-back-company-donates-tattoo-removal-laser-to-gang-rehabilitation-and-re-entry-program/2460597/Cutera, Inc. is donating an enlighten tatoo removal laser along with clinical training and service to Homeboy Industries, a gang rehabilitation and re-entry program in Los Angeles. Homeboy Industries provides parenting classes, anger management and tattoo removal to support former
- Ilumya Shows 5-Year Sustained Efficacy and Safety in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/ilumya-shows-5-year-sustained-efficacy-and-safety-in-moderate-to-severe-plaque-psoriasis/2460596/Patients with moderate-to-severe plaque psoriasis who continued to receive Ilumya (tildrakizumab-asmn) through five years of continuous treatment maintained consistent and extensive skin clearance with no new safety signals, according to Phase 3 data from the combined reSURFACE 1 and reSURFACE 2
- New Bimekizumab Phase 3 Data Presented at EADVhttps://practicaldermatology.com/news/new-bimekizumab-phase-3-data-presented-at-eadv/2460594/UCB shared detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults with moderate to severe plaque psoriasis. These findi